Tag Archives: Dana-Farber Cancer Institute

August, 2018

2 August
Lilly and Dana-Farber Cancer Institute Extend Cancer Research Collaboration

INDIANAPOLIS, July 30, 2018 /PRNewswire/ — Eli Lilly and Company(NYSE: LLY) today announced a three-year extension of its cancer research collaboration with Dana-Farber Cancer Institute. Since 2015, scientists from Lilly and Dana-Farber have been working together on pre-clinical and clinical studies, molecular analyses of patient samples and the design and conduct of clinical trials to …
Share

4 August
New Research Shows the Power of Radiomics to Improve Precision Medicine

TAMPA, Fla. (Aug. 3, 2017) – Precision medicine has become the leading innovation of cancer treatment. Patients are routinely treated with drugs that are designed to target specific tumors and molecules. Despite the progress that has been made in targeted cancer therapies, the path has been slow and scientists have …
Share

10 February
Study Finds Genetic Profiling Can Guide Stem Cell Transplantation for Patients with Myelodysplastic Syndrome

A single blood test and basic information about a patient’s medical status can indicate which patients with myelodysplastic syndrome (MDS) are likely to benefit from a stem cell transplant, and the intensity of pre-transplant chemotherapy and/or radiation therapy that is likely to produce the best results, according to new research …
Share

9 December
Personalized Cancer Vaccine is Associated with Promising outcomes for Patients with AML

A personalized cancer vaccine markedly improved outcomes for patients suffering from acute myeloid leukemia (AML), a potentially lethal blood cancer, in a clinical trial led by investigators at Beth Israel Deaconess Medical Center (BIDMC). The product of a long-term collaboration among investigators at the Cancer Center at BIDMC and Dana-Farber …
Share

18 November
Large-Scale Cancer Gene Profiling is Feasible but Faces Barriers

Researchers leading the largest genomic tumor profiling effort of its kind say such studies are technically feasible in a broad population of adult and pediatric patients with many different types of cancer, and that some patients can benefit by receiving precision drugs targeted to their tumors’ mutations or being enrolled …
Share

12 October
Daiichi Sankyo and Dana-Farber Cancer Institute Enter Lung Cancer Research Collaboration

TOKYO and PARSIPPANY, N.J. and BOSTON, Oct. 12, 2016 /PRNewswire/ — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and the Dana-Farber Cancer Institute today announced a preclinical research collaboration focused on lung cancer. A team of scientists led by Pasi A. Jänne, MD, PhD, Director, Lowe Center for Thoracic Oncology, …
Share

12 February
Study Finds More Young Women with Breast Cancer are Undergoing Genetic Testing

The vast majority of young women with breast cancer are being tested for mutations in the cancer-susceptibility genes BRCA1 and BRCA2, a new study led by Dana-Farber Cancer Institute investigators suggests, and many of them are using the results of those tests to guide their treatment. The study, published in …
Share